Abstract
Objectives
Over the past decade, several systemic agents as docetaxel, cabazitaxel, sipuleucel-T, abiraterone and enzalutamide have improved overall survival (OS) in metastatic prostate cancer (mPCa) patients. However, to date the OS benefit was not demonstrated in population-based analysis.
Methods
Between 2004 and 2014, 19,047 men with de novo mPCa were identified within the Surveillance Epidemiology and End Results database. Median year of diagnosis resulted in two groups: historical (2004–2008) and contemporary (2009–2014). Due to potentially important differences according to year of diagnosis, we relied on propensity score matching. Propensity-score-matched Kaplan–Meier analyses and Cox regression models (CRMs) tested cancer-specific mortality (CSM) free survival and overall mortality (OM) free survival according to treatment period.
Results
The propensity-score-matched cohort consisted of 8596 patients with mPCa. Of those, 4298 (50.0%) were historical (2004–2008) and 4298 (50.0%) were contemporary (2009–2014). CSM free survival rates and OM free survival rate were 32 versus 36 months (p < 0.0001) and 26 versus 29 months (p < 0.0001) for, respectively, historical and contemporary patients. In multivariable CRMs, patients diagnosed in contemporary years had lower CSM (HR 0.88; CI 0.82–0.93) and OM (HR 0.88; CI 0.84–0.93) risks compared to historical counterpart (all p < 0.0001).
Conclusion
This population-based study provides the first evidence of improved CSM free survival and OM free survival in patients with de novo mPCa since the introduction of several systemic agents for CRPC patients.
Similar content being viewed by others
References
Tangen CM, Hussain MHA, Higano CS et al (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188:1164–1169. https://doi.org/10.1016/j.juro.2012.06.046
Wu JN, Fish KM, Evans CP et al (2014) No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 120:818–823. https://doi.org/10.1002/cncr.28485
Teoh JYC, Ng C-F (2016) Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective. Int Urol Nephrol 48:1429–1435. https://doi.org/10.1007/s11255-016-1337-5
Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630–642. https://doi.org/10.1016/j.eururo.2016.08.002
Miyake H, Sakai I, Harada K et al (2012) Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old. Int Urol Nephrol 44:1697–1703. https://doi.org/10.1007/s11255-012-0223-z
Pan Y, Jin H, Chen W et al (2014) Docetaxel with or without zoledronic acid for castration-resistant prostate cancer. Int Urol Nephrol 46:2319–2326. https://doi.org/10.1007/s11255-014-0824-9
Petrylak DP, Tangen CM, Hussain MHA et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520. https://doi.org/10.1056/NEJMoa041318
Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512. https://doi.org/10.1056/NEJMoa040720
de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet Lond Engl 376:1147–1154. https://doi.org/10.1016/S0140-6736(10)61389-X
Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422. https://doi.org/10.1056/NEJMoa1001294
Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 24:3089–3094. https://doi.org/10.1200/JCO.2005.04.5252
de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005. https://doi.org/10.1056/NEJMoa1014618
Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983–992. https://doi.org/10.1016/S1470-2045(12)70379-0
Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197. https://doi.org/10.1056/NEJMoa1207506
Noone AM, Cronin KA, Altekruse SF, Howlader N, Lewis DR, Petkov VI, Penberthy L (2017) Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992–2013. Cancer Epidemiol Biomarkers Prev 26(4):632–641. https://doi.org/10.1158/1055-9965.EPI-16-0520
National Cancer Institute Surveillance, Epidemiology, and End Results Prostate-Specific Antigen Working Group, Adamo MP, Boten JA et al (2017) Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries. Cancer 123:697–703. https://doi.org/10.1002/cncr.30401
Mnatzaganian G, Davidson DC, Hiller JE, Ryan P (2015) Propensity score matching and randomization. J Clin Epidemiol 68:760–768. https://doi.org/10.1016/j.jclinepi.2015.01.002
Unger JM, Hershman DL, Martin D et al (2015) The diffusion of docetaxel in patients with metastatic prostate cancer. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju412
Marchioni M, Bandini M, Pompe RS et al (2017) Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. Int Urol Nephrol. https://doi.org/10.1007/s11255-017-1703-y
Financial support
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
This research did not receive any specific grant.
Rights and permissions
About this article
Cite this article
Bandini, M., Pompe, R.S., Marchioni, M. et al. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. Int Urol Nephrol 50, 71–78 (2018). https://doi.org/10.1007/s11255-017-1744-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-017-1744-2